Aldeyra Therapeutics, Inc. (ALDX) Balance Sheet

The steady reduction in total assets suggests that the company is consuming its capital reserves to sustain R&D activities. This trajectory indicates that the business model remains entirely dependent on external financing or milestone payments to maintain its operational viability.

While the current ratio remains above 2.5, the absolute decline in cash reserves highlights the high cost of maintaining late-stage ocular programs. Investors should monitor whether this liquidity level is sufficient to reach a commercial inflection point without necessitating further dilutive equity offerings.

The low debt load is a prudent choice for a pre-revenue biotech, as it avoids interest expense burdens that would further exacerbate net losses. However, the reliance on equity financing implies that shareholders remain exposed to significant dilution risk as the company seeks to extend its cash runway.

The persistent growth of the accumulated deficit underscores the high-risk nature of the company's R&D-heavy business model. This trend suggests that the equity base is being eroded by ongoing losses, placing increased pressure on the success of the reproxalap program to eventually reverse this long-term trend.